5,444 Shares in GlaxoSmithKline PLC (GSK) Acquired by Elgethun Capital Management

Elgethun Capital Management bought a new stake in GlaxoSmithKline PLC (NYSE:GSK) during the fourth quarter, Holdings Channel reports. The institutional investor bought 5,444 shares of the pharmaceutical company’s stock, valued at approximately $210,000.

Several other large investors also recently modified their holdings of the company. Carroll Financial Associates Inc. increased its position in shares of GlaxoSmithKline PLC by 0.3% in the third quarter. Carroll Financial Associates Inc. now owns 8,405 shares of the pharmaceutical company’s stock worth $362,000 after buying an additional 26 shares in the last quarter. Mission Wealth Management LLC increased its position in shares of GlaxoSmithKline PLC by 0.6% in the fourth quarter. Mission Wealth Management LLC now owns 6,826 shares of the pharmaceutical company’s stock worth $263,000 after buying an additional 40 shares in the last quarter. Homrich & Berg increased its position in shares of GlaxoSmithKline PLC by 0.7% in the third quarter. Homrich & Berg now owns 6,509 shares of the pharmaceutical company’s stock worth $281,000 after buying an additional 44 shares in the last quarter. Eads & Heald Investment Counsel increased its position in shares of GlaxoSmithKline PLC by 0.6% in the third quarter. Eads & Heald Investment Counsel now owns 7,149 shares of the pharmaceutical company’s stock worth $308,000 after buying an additional 45 shares in the last quarter. Finally, Cypress Wealth Advisors LLC increased its position in shares of GlaxoSmithKline PLC by 0.6% in the second quarter. Cypress Wealth Advisors LLC now owns 7,977 shares of the pharmaceutical company’s stock worth $346,000 after buying an additional 50 shares in the last quarter. 8.41% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 40.92 on Friday. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58. The firm’s 50-day moving average price is $39.32 and its 200 day moving average price is $40.85. The firm has a market cap of $99.60 billion, a PE ratio of 88.19 and a beta of 0.94.

GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, February 8th. The pharmaceutical company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.04. GlaxoSmithKline PLC had a return on equity of 100.68% and a net margin of 3.11%. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.74 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 13th. Shareholders of record on Friday, February 24th will be issued a dividend of $0.571 per share. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $2.28 annualized dividend and a yield of 5.58%. The ex-dividend date is Wednesday, February 22nd. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 389.36%.

This piece was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another domain, it was copied illegally and reposted in violation of international trademark and copyright law. The original version of this piece can be accessed at http://sleekmoney.com/5444-shares-in-glaxosmithkline-plc-gsk-acquired-by-elgethun-capital-management/1666186.html.

A number of research analysts recently commented on the company. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Tuesday, January 31st. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, October 25th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, December 21st. Investec assumed coverage on GlaxoSmithKline PLC in a report on Thursday, October 20th. They issued a “buy” rating for the company. Finally, Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline PLC in a report on Monday, November 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have given a buy rating to the company. GlaxoSmithKline PLC has an average rating of “Buy” and a consensus target price of $48.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/5444-shares-in-glaxosmithkline-plc-gsk-acquired-by-elgethun-capital-management/1666186.html

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *